Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fresenius Kabi Oncology

- PMLiVE

Improving outcomes in oncology: patient centricity and mental health

A key challenge in healthcare is how to proactively address unmet needs using patient-centric campaigns and resources, particularly in a time when ‘in-person’ care is limited. How can this be...

Mednet Group

- PMLiVE

World Cancer Day – February 2022

World Cancer Day is celebrated around the world in February in February and innovative Trials wants to take this opportunity to raise awareness around cancer

Innovative Trials

- PMLiVE

No green light from NICE for innovative cancer treatments

The Institute of Cancer Research is asking for more flexibility and consideration to make it easier for cancer patients to access new treatments on the NHS

- PMLiVE

FDA issues approval for Janssen’s HIV drug Cabenuva

The injectable treatment for adults with HIV can be administered every two months

- PMLiVE

Janssen submits marketing authorisation to EMA for teclistamab

The drug has been developed to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer

- PMLiVE

Janssen’s Tremfya receives positive results for active psoriatic arthritis

The drug demonstrated positive joint efficacy and ranked highest for skin clearance when compared to existing therapies

- PMLiVE

BMS and Century Therapeutics agree on deal potentially worth over $3bn

The collaboration unites Century’s iPSC-derived allogeneic cell therapy line with BMS’s record in developing oncology drugs and cell therapies

- PMLiVE

Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies

The strategic research collaboration between the two companies aims to develop AI-driven pipeline of precision-engineered therapies

- PMLiVE

Sanofi to pay $1.2bn to acquire Amunix and its ‘stealth’ technology

Sanofi will acquire Amunix’s next-generation protein engineering tech that allows biologic drugs to circulate in ‘stealth’ mode, becoming active only in diseased tissues

- PMLiVE

Novartis strengthens links with BeiGene in a deal that could be worth up to $1bn

Novartis is to pay $300m upfront to BeiGene in a multifaceted deal to enhance its oncology portfolio and expand coverage of the Chinese market

- PMLiVE

AstraZeneca’s Saphnelo to be approved in Europe for lupus

The EMA is set to approve the first new treatment for systemic lupus erythematosus in Europe in more than a decade

- PMLiVE

Lilly and Foghorn sign oncology deal

Eli Lilly has teamed up with Foghorn Therapeutics to develop drugs that target the chromatin regulatory system using Foghorn's proprietary Gene Traffic Control platform

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links